Janssen’s Balversa meets primary endpoint in Phase 3 study of UC patients
Balversa, a once-daily, oral FGFR kinase inhibitor, met the primary endpoint of overall survival (OS) and reduced the…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 Jun 23
Balversa, a once-daily, oral FGFR kinase inhibitor, met the primary endpoint of overall survival (OS) and reduced the…
06 Jun 23
Brella received clearance from the US Food and Drug Administration (FDA) in April this year for the management…
06 Jun 23
Seegene certifies diagnostic assays for digestive, respiratory, women's diseases, and human papillomavirus to meet IVDR requirements. New regulation…
06 Jun 23
New EVOQ DART-TQ+ system for chromatography-free triple-quadrupole mass spectrometry for point-of-need (PoN) routine analysis. Launch of impact™ II…
05 Jun 23
The late-stage trial evaluated patients with Stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-)…
05 Jun 23
Vorasidenib met its primary endpoint of progression free survival per the blinded independent review committee and achieved its…
05 Jun 23
Starpharma is progressing discussions with potential commercial partners in Malaysia, with the view of distributing VIRALEZE through local…
02 Jun 23
Lynparza is a PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours…
02 Jun 23
The European approval is based on Phase 3 data from the SUNSHINE and SUNRISE trials which enrolled more…
02 Jun 23
SYMPLIFY Results Demonstrate Strong Performance of GRAIL’s Multi-Cancer Early Detection Methylation-Based Platform in Individuals Presenting With Non-Specific Signs…